Tobrex, eye drops 0.3% 5 ml

Tobrex eye drops contain tobramycin, a broad-spectrum antibiotic of the aminoglycoside group. Bactericidal effect of the drug extends to Streptococcus and Staphylococcus bacteria, Klebsiella, Escherichia coli, diphtheria bacteria.

In low concentrations the action is bacteriostatic (blocks 30S ribosome subunit and disturbs protein synthesis) and in higher concentrations it is bactericidal (disturbs cytoplasmic membrane function, causing death of microbial cell).

Highly active against Staphylococcus spp. (including Staphylococcus aureus, Staphylococcus epidermidis /coagulase-negative and coagulase-positive/ and penicillin-resistant strains); Streptococcus spp.including α-β-haemolytic species, some non-haemolytic species, Streptococcus pneumoniae); Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis (indole-negative) and indole-positive species of Proteus spp, Haemophilus influenzae, Haemophilus aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus (Herellea vaginacola), some Neisseria spp. species (including Neisseria gonorrhoeae).

Pharmacokinetics

In local administration systemic absorption is low.

Indications

Infections of the eye and its appendages:
– blepharitis;
– conjunctivitis;
– keratoconjunctivitis;
– blepharoconjunctivitis;
– keratitis;
– iridocyclitis.
Prevention of postoperative infections.

Pharmacological effect

Tobrex eye drops contain tobramycin, a broad-spectrum antibiotic from the aminoglycoside group. The bactericidal effect of the drug extends to streptococcal and staphylococcal bacteria, Klebsiella, Escherichia coli, and diphtheria bacteria.

At low concentrations it acts bacteriostatically (blocks the 30S ribosomal subunit and disrupts protein synthesis), and at higher concentrations it acts bactericidal (disturbs the function of cytoplasmic membranes, causing the death of microbial cells).

Highly active against Staphylococcus spp. (including Staphylococcus aureus, Staphylococcus epidermidis /coagulase-negative and coagulase-positive/, as well as strains resistant to penicillin); Streptococcus spp. (including α-β-hemolytic species, some non-hemolytic species, Streptococcus pneumoniae); Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis (indole-negative) and indole-positive species Proteus spp., Haemophilus influenzae, Haemophilus aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus (Herellea vaginacola), some Neisseria species spp. (including Neisseria gonorrhoeae).

Pharmacokinetics

When applied topically, systemic absorption is low.

Special instructions

During treatment with the drug, wearing contact lenses is unacceptable.

Long-term use of Tobrex eye drops, as with the use of other antibiotics, can lead to increased growth of resistant microorganisms (including fungi). It is recommended to do cultures before and after the end of treatment if the clinical result is unsatisfactory.

Impact on the ability to drive vehicles and operate machinery

It is not recommended to drive a car or work with complex machinery, machines or any other complex equipment that requires clear vision for patients who temporarily experience blurred vision after instillation of Tobrex.

Active ingredient

Tobramycin

Composition

Active substance:

Pregnancy

There is no sufficient experience with the use of the drug during pregnancy and lactation (breastfeeding). It is possible to use Tobrex eye drops in pregnant women and nursing mothers when the expected therapeutic effect outweighs the potential risk of side effects.

Use in children

There is no sufficient experience with the use of Tobrex eye drops in children. The drug can be used in children if the expected therapeutic effect outweighs the potential risk of side effects.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Local. An allergic reaction, accompanied by itching and swelling of the eyelids, conjunctival hyperemia, and lacrimation.

Interaction

In case of simultaneous administration of tobramycin topically with systemic aminoglycoside antibiotics, systemic side effects may be increased.

Overdose

Symptoms: punctate keratitis, erythema, increased lacrimation, itching and swelling of the eyelid.

Storage conditions

At 8–30 °C

Shelf life

3 years

Manufacturer

Alcon-Couvreur, Belgium